MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7

Li, Qiang; Zou, Chaoxia; Zou, Chendan; Han, Zhongjing; Xiao, Haifeng; Wei, Huiyan; Wang, Wei; Zhang, Lei; Zhang, Xueying; Tang, Qingchao; Zhang, Chunjing; Ji, Tao; Wang, Xishan; Gao, Xu

doi:10.1016/j.canlet.2013.02.029

Cited by 109 publications

(101 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Generally, expression of miR25 is higher in cancer cells of epithelial origin, and in tumor stroma, compared with normal colon mucosa (45,46). We showed that expression of miR25-3p is lower in patients with colon cancer with distant metachronous metastases compared with those without distant metastases.…”

Section: Discussionmentioning

confidence: 66%

“…As discussed previously (45), function of miR25 can be oncogenic or tumor repressive depending on the tissue type. Generally, expression of miR25 is higher in cancer cells of epithelial origin, and in tumor stroma, compared with normal colon mucosa (45,46).…”

Section: Discussionmentioning

confidence: 90%

“…Taken together, these data suggest that in colon cancer, expression of miR25-3p, after initial increase, might need to be decreased to some extent to enable the initiation of the distant metastasis process. Indeed, Li and colleagues showed that overexpression of miR25 suppressed migratory ability of colon cancer cells in vitro and decreased tumorigenic potential in a colon cancer xenografts (45). In addition, Baffa and colleagues reported decreased expression of miR25 in metastases compared with their associated primary colon tumor (48).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

MicroRNA Classifier and Nomogram for Metastasis Prediction in Colon Cancer

Goossens-Beumer

Derr

Buermans

et al. 2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Colon cancer prognosis and treatment are currently based on a classification system still showing large heterogeneity in clinical outcome, especially in TNM stages II and III. Prognostic biomarkers for metastasis risk are warranted as development of distant recurrent disease mainly accounts for the high lethality rates of colon cancer. miRNAs have been proposed as potential biomarkers for cancer. Furthermore, a verified standard for normalization of the amount of input material in PCR-based relative quantification of miRNA expression is lacking.Methods: A selection of frozen tumor specimens from two independent patient cohorts with TNM stage II-III microsatellite stable primary adenocarcinomas was used for laser capture microdissection. Next-generation sequencing was performed on small RNAs isolated from colorectal tumors from the Dutch cohort (N ¼ 50). Differential expression analysis, comparing in metastasized and nonmetastasized tumors, identified prognostic miRNAs.

show abstract

Section: Discussionmentioning

confidence: 66%

Section: Discussionmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

MicroRNA Classifier and Nomogram for Metastasis Prediction in Colon Cancer

Goossens-Beumer

Derr

Buermans

et al. 2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…Cisplatin sensitivity was increased by overexpression of miR-451 in lung cancer cells (41). Another downregulated miRNA, miR-25, may function as a tumor suppressor that inhibits cell proliferation and migration by targeting Smad 7 in colon cancer (44) and EZH2 in anaplastic thyroid carcinoma (45). Finally, studies have suggested a tumor suppressor role for miR-139-5p, which is downregulated in various types of cancer, including endometrial serous adenocarcinoma (46), breast carcinoma (47), glioblastoma (48), bladder cancer (49), basal cell carcinoma (50) and esophageal squamous cell carcinoma (51).…”

Section: Discussionmentioning

confidence: 99%

MicroRNA screening identifies circulating microRNAs as potential biomarkers for osteosarcoma

Li¹,

Zhang²,

Liu³

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. MicroRNAs (miRNAs) are a family of small non-protein coding RNAs, which regulate the expression of a wide variety of genes at the post-transcriptional level to control numerous biological and pathological processes. Various circulating miRNAs have been identified as potential diagnostic and prognostic biomarkers in multiple types of cancer and disease. The aim of the present study was to identify potential miRNA biomarkers for the early diagnosis and relapse prediction of osteosarcoma (OS). miRNA profiling was performed on serum from patients with osteosarcoma and healthy controls. All putative miRNAs were verified by reverse transcription-quantitative polymerase chain reaction analysis of 20 pre-therapeutic OS patients and 20 healthy individuals. The expression of miR-106a-5p, miR16-5p, miR-20a-5p, miR-425-5p, miR451a, miR-25-3p and miR139-5p was demonstrated to be downregulated in the serum of OS patients when compared with that of the healthy controls. Receiver-operating characteristic curve analyses indicated that these 7 miRNAs may be used as diagnostic biomarkers with the ability to discriminate between the healthy cohort and patients with OS. These results provide novel insights into the use of miRNAs in early blood screening for OS.

show abstract

“…In the present study, plasma miR-21 expression levels were upregulated in the non-benefit group compared with the benefit group, and high expression of miR-21 was associated with poor PFS. miR-25 is known to be dysregulated in various types of cancer, and to have oncogenic and tumor suppressive functions (48,49). In NSCLC cell lines and human tissue, miR-25 …”

Section: Discussionmentioning

confidence: 99%

Evaluation of plasma microRNA levels to predict insensitivity of patients with advanced lung adenocarcinomas to pemetrexed and platinum

Zhu

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Pemetrexed combined with platinum is a first-line therapy used to treat patients with advanced non-small cell lung cancer (NSCLC) that exhibit negative or unknown epidermal growth factor receptor (EGFR) mutational status or anaplastic lymphoma kinase (ALK) rearrangements. Lung adenocarcinoma (LAC) is the primary type of NSCLC. In order to prevent overtreatment, it is necessary to identify patients with LAC who may not benefit from certain chemotherapies. Patients recruited in the present study (n=129) were diagnosed with advanced LAC and received first-line pemetrexed and platinum-based chemotherapy. A microRNA (miR) microarray was used to screen the plasma miR expression profiles in a screening set of eight patients prior to and following treatment. Specifically, plasma miR-25, miR-21, miR-27b, miR-326, miR-483-5p and miR-920 were selected for reverse transcription-quantitative polymerase chain reaction analysis in a training set (n=44) prior to treatment. The screening and training set patients were all non-smokers with no prior history of serious or chronic disease. The ∆∆Cq values of these miRs were compared between the group that showed benefit from pemetrexed and platinum treatment and the group that did not. Consequently, the ∆∆Cq values of miR-25, miR-21, miR-27b and miR-326 were further determined in a validation set (n=77). The results of the present study demonstrate that plasma expression levels of miR-25, miR-21, miR-27b and miR-326, in the training and validation sets prior to treatment, were significantly different between the benefit and non-benefit groups (P≤0.001). The expression of miR-25, miR-21, miR-27b and miR-326 was upregulated in the non-benefit group and this elevation was positively correlated with decreased progression-free survival (PFS; P≤0.001). In addition, the predictive power of each miR was evaluated through receiver operating characteristic curves, in which miR-25 exhibited the highest degree of accuracy (area under the curve, 0.926; 95% confidence interval, 0.881-0.971). These results indicate that overexpression of plasma miR-25, miR-21, miR-27b and miR-326, prior to treatment, in patients with advanced LAC is predictive of non-benefit from first-line pemetrexed and platinum-based chemotherapy, and is associated with decreased PFS. Among these four miRs, miR-25 exhibited the highest degree of accuracy in predicting insensitivity, suggesting it is the most promising biomarker.

show abstract

MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7

Cited by 109 publications

References 30 publications

MicroRNA Classifier and Nomogram for Metastasis Prediction in Colon Cancer

MicroRNA Classifier and Nomogram for Metastasis Prediction in Colon Cancer

MicroRNA screening identifies circulating microRNAs as potential biomarkers for osteosarcoma

Evaluation of plasma microRNA levels to predict insensitivity of patients with advanced lung adenocarcinomas to pemetrexed and platinum

Contact Info

Product

Resources

About